Speaker(s): 

Dr Kyle D Fistner, DO, Addiction Medicine Fellow - has nothing to disclose.

Dr Linda Okoro, MD, Addiction Medicine Fellow - has nothing to disclose.

Moderator(s): 

Dr Joseph Valdez, MD, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

Dr Fistner

• Understand the ever-changing substance use landscape and discuss Xylazine and a new adulterant
• Understand the use of test strips as a harm reduction response
• Discuss a Quality Improvement project performed through Geisinger Addiction Medicine Fellowship Program

Dr Okoro

• Compare retention rates in AUD patients on MAT with and without counseling/12-step involvement.

• Examine how mental health and socioeconomic factors impact retention.

• Identify and address barriers to retention.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Margaret Jarvis, MD, Jessica Sevecke-Hanrahan, PhD, Jessie Goldhirsh, MD, Kati Mahlmann, LCSW, Priscilla Riley, LPC, Imad Melhem, MD, and DeAnn Hansum, PA-C have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None